Editing Α-Methyltryptamine (section)

===Legality===
====Australia====
The 5-methoxy analogue, [[5-MeO-αMT]] is [[Standard for the Uniform Scheduling of Drugs and Poisons#Schedule 9 Prohibited Substance|schedule 9]] in Australia and αMT would be controlled as an analogue of this.<ref name="urlErowid 5-MeO-AMT Vault : Legal Status">{{cite web | url = http://www.erowid.org/chemicals/5meo_amt/5meo_amt_law.shtml | work = Erowid Vault | title = 5-MeO-AMT: Legal Status }}</ref>

====Austria====
αMT is placed under Austrian law (NPSG) Group 6.<ref name="who.int"/>

====Canada====
Canada has no mention of αMT in the [[Controlled Drugs and Substances Act]].<ref name="urlCDSA List">{{cite web | url = http://isomerdesign.com/Cdsa/schedule.php?structure=C | title = CSDA | access-date = 2011-06-05 | archive-date = 2011-09-28 | archive-url = https://web.archive.org/web/20110928152752/http://isomerdesign.com/Cdsa/schedule.php?structure=C | url-status = dead }}</ref>

====China====
As of October 2015 αMT is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | trans-title = Notice on the issuance of the "Regulations on the Listing of Non-Medicinal Narcotic Drugs and Psychotropic Drugs" | publisher=China Food and Drug Administration | date=27 September 2015 | language=zh | access-date=1 October 2015 | archive-url=https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | archive-date=1 October 2015 | url-status=dead }}</ref>

====Denmark====
In Denmark (2010), the Danish Minister for the Interior and Health placed αMT to their lists of controlled substances (List B).<ref name="who.int">{{cite web| url = https://www.who.int/medicines/areas/quality_safety/4_20_Review.pdf | archive-url = https://web.archive.org/web/20180916024447/https://www.who.int/medicines/areas/quality_safety/4_20_Review.pdf | archive-date = 16 September 2018 | title = Alpha-methyltryptamine (AMT) Critical Review Report Agenda item 4.20 | author = Expert Committee on Drug Dependence Thirty-sixth Meeting | location = Geneva | date = June 2014 | publisher = World Health Organization (WHO) }}</ref>

====Finland====
AMT, alfa-methyltryptamine, is a controlled drug in Finland.<ref>{{cite web | title = Lääkeluettelon Aineet, Liite 1, Bilaga 1.3 | trans-title = Substances of the drug list, Appendix 1. Attachment 1.3 | url = http://www.finlex.fi/data/sdliite/liite/6194.pdf | archive-url = https://web.archive.org/web/20150510154257/http://www.finlex.fi/data/sdliite/liite/6194.pdf | url-status = dead | archive-date = May 10, 2015 | work = Finlex Data Bank | publisher = Finnish Ministry of Justice }}</ref>

====Germany====
αMT is listed under the Narcotics Act in schedule 1 (narcotics not eligible for trade and medical prescriptions) in Germany.<ref name="who.int"/>

====Hungary====
αMT was controlled on the Schedule C list in Hungary in 2013.<ref name="who.int"/>

====Lithuania====
In Lithuania (2012), αMT is controlled as a tryptamine derivative put under control in the 1st list of Narcotic Drugs and Psychotropic Substances which use is prohibited for medical purposes.<ref name="who.int"/>

====Slovakia====
αMT was placed in 2013 on the List of Hazardous Substances in Annex, § 2 in Slovakia.<ref name="who.int"/>

====Slovenia====
αMT appeared on the Decree on Classification of Illicit Drugs in Slovenia (2013).<ref name="who.int"/>

====Spain====
αMT is legal in Spain.<ref>{{cite web|url=https://www.aemps.gob.es/medicamentosUsoHumano/estupefacientesPsicotropos/home.htm|title=Medicamentos de Uso Humano - Estupefacientes y Psicótropos | trans-title = Medicines for Human Use - Narcotics and Psychotropic Substances |website=Agencia Española de Medicamentos y Productos Sanitarios [Spanish Agency for Medicines and Health Products] |access-date=2019-01-01|archive-date=2019-01-02|archive-url=https://web.archive.org/web/20190102002336/https://www.aemps.gob.es/medicamentosUsoHumano/estupefacientesPsicotropos/home.htm|url-status=dead}}</ref>

====Sweden====
[[Riksdag|''Sveriges riksdags'']] health ministry [[:sv:Statens folkhälsoinstitut|''Statens folkhälsoinstitut'']] classified αMT as "health hazard" under the act [[:sv:Lagen om förbud mot vissa hälsofarliga varor|''Lagen om förbud mot vissa hälsofarliga varor'']] (translated ''Act on the Prohibition of Certain Goods Dangerous to Health'') as of Mar 1, 2005, in their regulation SFS 2005:26 listed as alfa-metyltryptamin (AMT), making it illegal to sell or possess.<ref name='Swedenlaw'>{{citation | contribution = Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor [Ordinance amending the Ordinance (1999:58) on the prohibition of certain goods hazardous to health] | title = Lagen om förbud mot vissa hälsofarliga varor - SFS 2005:26 | trans-title = The Act on the Prohibition of Certain Goods Hazardous to Health - SFS 2005:26 | date = February 2005 | contribution-url = http://www.notisum.se/rnp/sls/sfs/20050026.pdf | access-date = 2013-10-07 | language = sv | archive-date = 2013-09-29 | archive-url = https://web.archive.org/web/20130929063138/http://www.notisum.se/rnp/sls/sfs/20050026.pdf | url-status = dead }}</ref>

====United Kingdom====
αMT was made illegal in the United Kingdom as of 7 January 2015, along with [[5-MeO-DALT]].<ref>{{cite web|url=http://www.legislation.gov.uk/uksi/2014/3277/introduction/made/data.htm|title=The Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014|website=www.legislation.gov.uk}}</ref>
This was following the events of 10 June 2014 when the [[Advisory Council on the Misuse of Drugs]] recommended that αMT be scheduled as a class A drug by updating the blanket ban clause on tryptamines.<ref name="ACMD tryptamines">{{cite web | url=https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/318693/UpdateGenericDefinitionTryptamines.pdf | title=Update of the Generic Definition for Tryptamines | publisher=UK Home Office | date=10 June 2014 | access-date=10 June 2014 | author=ACMD|page=12}}</ref>

====United States====
The [[Drug Enforcement Administration]] (DEA) placed αMT temporarily in schedule I of the Controlled Substances Act (CSA) on April 4, 2003, pursuant to the temporary scheduling provisions of the CSA (68 FR16427). On September 29, 2004, αMT was permanently controlled as a schedule I substance under the CSA (69FR 58050).<ref>{{cite news|title=Alpha-methyltryptamine |date=April 2013 |url=http://www.deadiversion.usdoj.gov/drug_chem_info/amt.pdf |work=DEA Office of Diversion Control |access-date=2013-10-10 |archive-url=https://web.archive.org/web/20131017084419/http://www.deadiversion.usdoj.gov/drug_chem_info/amt.pdf |archive-date=2013-10-17 |url-status=live }}</ref>